Elraglusib Trial: Survival Outcomes In Metastatic Pancreatic Cancer

Key Takeaways

• In a phase 2 metastatic pancreatic cancer trial, longer overall survival and higher one- and two-year survival were observed with elraglusib plus chemotherapy.
• The randomized phase 2 study enrolled 233 patients at 60 sites in six countries and compared chemotherapy alone with chemotherapy plus elraglusib.
• Adverse effects were described as manageable, with low white blood cell counts, fatigue, and temporary vision changes.

In a randomized phase 2 metastatic pancreatic cancer trial, investigators reported that adding elraglusib to standard chemotherapy was associated with a 38% lower risk of death versus chemotherapy alone. Patients with metastatic disease were randomly assigned to combination treatment or chemotherapy without the study drug.

The study enrolled 233 patients with metastatic pancreatic cancer across 60 sites in six countries in North America and Europe. Participants were assigned to receive standard chemotherapy alone or the same chemotherapy with elraglusib added to the regimen. The available description emphasized the multicenter geography and randomized allocation rather than detailing eligibility criteria or follow-up methods.

Median overall survival was 10.1 months with elraglusib plus chemotherapy and 7.2 months with chemotherapy alone. At one year, 44% of patients in the combination group were alive, compared with 22% in the control group. At two years, about 13% of patients receiving elraglusib were alive, while no patients remained alive in the chemotherapy-alone group.

Adverse effects were broadly consistent with chemotherapy, though they were somewhat more common with elraglusib. The most frequent events included low white blood cell counts, fatigue, and temporary vision changes. The vision changes were reported as reversible rather than persistent.

Elraglusib targets GSK-3 beta and acts on the tumor microenvironment. Researchers observed increases in cancer-fighting cells within tumors among patients who received the drug. They also noted that certain immune-related blood markers present at the start of the trial were associated with longer survival among patients who received the drug, while describing those associations as preliminary. The authors said the findings support cautious optimism, while also emphasizing the need for confirmation in a larger phase 3 program.